Found: 23
Select item for more details and to access through your institution.
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
- Published in:
- NPJ Vaccines, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41541-022-00564-z
- By:
- Publication type:
- Article
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.
- Published in:
- NPJ Vaccines, 2021, v. 6, n. 1, p. 1, doi. 10.1038/s41541-021-00402-8
- By:
- Publication type:
- Article
Durable natural killer cell responses after heterologous two-dose Ebola vaccination.
- Published in:
- NPJ Vaccines, 2021, v. 6, n. 1, p. 1, doi. 10.1038/s41541-021-00280-0
- By:
- Publication type:
- Article
Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine.
- Published in:
- Journal of Infectious Diseases, 2022, v. 226, n. 6, p. 979, doi. 10.1093/infdis/jiac142
- By:
- Publication type:
- Article
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
- Published in:
- Vaccines, 2024, v. 12, n. 2, p. 210, doi. 10.3390/vaccines12020210
- By:
- Publication type:
- Article
NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans.
- Published in:
- Vaccines, 2022, v. 10, n. 6, p. N.PAG, doi. 10.3390/vaccines10060884
- By:
- Publication type:
- Article
EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country.
- Published in:
- Clinical Trials, 2018, v. 15, n. 5, p. 436, doi. 10.1177/1740774518780678
- By:
- Publication type:
- Article
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.
- Published in:
- JAMA: Journal of the American Medical Association, 2017, v. 317, n. 10, p. 1075, doi. 10.1001/jama.2016.20644
- By:
- Publication type:
- Article
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
- Published in:
- PLoS ONE, 2022, v. 17, n. 10, p. 1, doi. 10.1371/journal.pone.0274906
- By:
- Publication type:
- Article
Accessing Maternal Health Services in Eastern Burma.
- Published in:
- PLoS Medicine, 2008, v. 5, n. 12, p. e250, doi. 10.1371/journal.pmed.0050250
- By:
- Publication type:
- Article
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine.
- Published in:
- Scientific Reports, 2016, p. 36355, doi. 10.1038/srep36355
- By:
- Publication type:
- Article
Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
- Published in:
- NPJ Vaccines, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41541-023-00767-y
- By:
- Publication type:
- Article
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1215302
- By:
- Publication type:
- Article
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine.
- Published in:
- Immunological Reviews, 2022, v. 310, n. 1, p. 47, doi. 10.1111/imr.13088
- By:
- Publication type:
- Article
Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria.
- Published in:
- Malaria Journal, 2011, v. 10, n. 1, p. 114, doi. 10.1186/1475-2875-10-114
- By:
- Publication type:
- Article
Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC.
- Published in:
- Malaria Journal, 2011, v. 10, n. 1, p. 49, doi. 10.1186/1475-2875-10-49
- By:
- Publication type:
- Article
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141687
- By:
- Publication type:
- Article
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
- Published in:
- 2019
- By:
- Publication type:
- journal article